Late-onset dysfunction of lumboperitoneal shunt in IIH

Key Points at a Glance

1. Delayed LP Shunt Failure in IIH

Idiopathic intracranial hypertension (IIH) is a disease characterized by elevated intracranial pressure (ICP) of unknown cause. It predominantly affects obese women of reproductive age. The incidence of IIH is increasing worldwide ¹⁾.

The revised Dandy criteria are used for the diagnosis of IIH. The specific diagnostic requirements are as follows.

Symptoms of increased intracranial pressure: headache, visual disturbances, etc.
Signs of increased intracranial pressure: papilledema, abducens nerve palsy
Imaging findings: CSF accumulation in the optic nerve sheath, empty sella turcica, flattening of the posterior globe
Lumbar puncture: normal CSF composition and elevated intracranial pressure

CSF diversion includes ventriculoperitoneal (VP) shunts and lumboperitoneal (LP) shunts. Both lower intracranial pressure in IIH, but shunting is often a temporary measure. LP shunt malfunction occurs relatively frequently, with an average time to failure reported as 5–10 years.

Because the clinical presentation is diverse, diagnosing delayed LP shunt malfunction can be difficult. Currently, many institutions have shifted to using VP shunts over LP shunts.

Q How many years does it take for LP shunt malfunction to occur?

Many reports indicate that the average time to LP shunt malfunction is 5 to 10 years. However, individual differences are large depending on BMI and catheter type. For details, see the section on “Causes and Risk Factors”.

2. Main Symptoms and Clinical Findings

Sherilyn Nguyen, Nicholas Kato, Salomon D Salama. When One Tap Isn’t Enough: A Case of Pseudotumor Cerebri Requiring Venous Sinus Stenting. Cureus. 2025 Oct 17; 17(10):e94778. Figure 1. PMCID: PMC12619920. License: CC BY.

A????????B?2?????????C?10????????????????????????????????????????????

Subjective Symptoms

LP shunt failure presents with symptoms similar to IIH recurrence. The main symptoms and their frequencies are as follows.

Headache: Most common, occurring in 83% of cases. In IIH overall, it appears in about 90% ¹⁾
Pulse-synchronous tinnitus: Occurs in 52%
Transient visual obscurations: Occur in 42%
Diplopia: Occurs in 24%

Headache in IIH initially presents as an intracranial hypertension type that worsens upon waking, but over time it becomes chronic and often shows migraine-like features (with photophobia, phonophobia, and nausea) ¹⁾.

Clinical Findings (Findings Confirmed by Physician Examination)

Papilledema is a typical finding in IIH, but it is not necessarily observed in LP shunt failure. It is usually bilateral and symmetric, but may be unilateral or asymmetric.

Clinical data in LP shunt dysfunction are as follows:

Opening pressure: Mean at diagnosis is 36 cm H₂O
Visual acuity: Mean initial visual acuity 20/32 (approximately 0.6), final visual acuity 20/25 (approximately 0.8)
Frisen grade of papilledema: Mean initial 1.8, mean maximum 2.3
Choroidal folds: May be present regardless of the presence or absence of papilledema

Visual field testing often reveals enlarged blind spots, nasal steps, and arcuate scotomas. In cases of long-term shunt failure, optic atrophy may occur.

3. Causes and Risk Factors

The reasons for requiring LP shunt revision are diverse. The main causes are listed below.

Obstruction: One of the most common causes
Over drainage: Causes symptoms of low intracranial pressure
Mechanical failure: Deterioration of valves or catheters
Catheter migration: Movement within the abdominal cavity or spinal canal
Catheter fracture: Damage due to long-term placement
Abdominal complications: Intestinal perforation, ileus, etc.
Lumbar spinal complications: Nerve root symptoms, spinal epidural abscess, etc.
Infection: May spread throughout the shunt

The use of Silastic catheters dramatically reduced occlusion and fracture rates. As a result, the lifespan of LP shunts was further extended.

The relationship between BMI and shunt survival is shown below.

BMI	Median shunt survival
<25.0 (healthy)	44 months
High BMI	18 months

In obese patients, technical difficulty in placing the catheter under the peritoneum is considered a factor in shortened survival.

Children have a higher risk of complications due to increased mechanical stress, changes in intrathecal tube size, and relative shortening of the catheter with growth. Therefore, delayed LP shunt failure is more common when the initial placement occurs in adulthood.

As risk factors for IIH itself, obesity and weight gain are the largest modifiable factors ²⁾. Endocrine disorders (Addison’s disease, hypoparathyroidism, steroid withdrawal) are also involved in the development of IIH ²⁾.

Q Does weight management affect shunt lifespan?

In patients with a BMI below 25.0, the median shunt survival is 44 months, whereas in high-BMI patients it is only 18 months. Technical difficulties in catheter placement are considered a contributing factor in obese patients.

4. Diagnosis and Examination Methods

In patients who have previously undergone LP shunt surgery, identifying the cause of recurrent symptoms relies on medical history and physical examination. The following tests are combined for evaluation.

Lumbar puncture: Initial pressure measurement is important. An opening pressure above 250 mmCSF meets the diagnostic criteria for IIH²⁾
X-ray shunt series: Imaging of the abdomen and pelvis to evaluate distal and proximal catheter breakage. For VP shunts, includes head, neck, chest, and abdomen.
Nuclear medicine study (shuntogram): A test to evaluate shunt patency.
Neurosurgery consultation: Recommended for checking shunt integrity and function.

The following ophthalmologic examinations are performed:

Fundus examination: Evaluates the presence and degree of papilledema.
Optical coherence tomography (OCT): Used for quantitative assessment of retinal nerve fiber layer thickness.
Automated perimetry: detects enlarged blind spot, nasal step, arcuate scotoma

Differential Diagnosis

Other causes of increased intracranial pressure besides LP shunt failure must be excluded.

Obstructive hydrocephalus
Cerebral venous sinus thrombosis
Decreased CSF absorption: after meningitis, subarachnoid hemorrhage
Intracranial space-occupying lesion

Differentiating between overdrainage (intracranial hypotension) and shunt failure (intracranial hypertension) is particularly important. Symptoms of both conditions overlap.

Intracranial hypertension

Headache: Tends to worsen when lying down.

Papilledema: Suggests elevated intracranial pressure.

Cause: Shunt obstruction or malfunction.

Intracranial Hypotension

Headache: Tends to worsen when standing.

Papilledema: Usually not present.

Cause: Excessive CSF drainage due to shunt.

Abducens nerve palsy, blurred vision, and headache can occur with both overdrainage and underdrainage, so caution is needed.

Q How to differentiate symptoms of shunt malfunction from overdrainage?

In intracranial hypertension, headache worsens in the supine position and is often accompanied by papilledema. In contrast, in intracranial hypotension, headache worsens in the upright position. However, since abducens nerve palsy and diplopia can occur in both conditions, measurement of opening pressure via lumbar puncture is important for differentiation.

5. Standard Treatment

Treatment of LP shunt failure usually requires shunt revision or replacement.

Shunt Surgery

Many institutions prefer VP shunt as the CSF diversion procedure for IIH. The reasons are as follows:

Low complication rate
Low reconstruction rate
Shortened average hospital stay due to shunt failure

VP shunt surgery has been reported to improve or stabilize vision in patients with rapidly worsening vision or in IIH patients with progressive visual impairment despite medical therapy or optic nerve sheath fenestration (ONSF).

In the UK, the use of ICP monitors, programmable valves, and anti-siphon valves is recommended¹⁾.

Optic Nerve Sheath Fenestration (ONSF)

ONSF is an option when medical treatment fails or when shunt reconstruction is not possible. It is suitable for patients with mild headache but severe visual decline and persistent optic disc edema¹⁾.

Complication rate: 10–15% overall
Risk of vision loss: 1–2% (due to central retinal artery occlusion or central retinal vein occlusion)
ONSF does not lower ICP, so it is not recommended for headache treatment¹⁾

Medication Therapy

Acetazolamide (Diamox): A carbonic anhydrase inhibitor that suppresses CSF production. Start at 250–500 mg twice daily, up to a maximum of 4 g/day¹⁾
In the IIHTT (2014), acetazolamide combined with weight loss improved mild to moderate visual field changes¹⁾
Can be used as a temporary measure even in patients with an LP shunt in place

Venous Stent Placement

Focal venous stenosis is found in 30–93% of IIH patients. Candidates are those with focal stenosis of the transverse or sigmoid sinus.

Headache improvement: up to 88%
Resolution of papilledema: 97%

Weight Loss and Lifestyle Guidance

For IIH, weight loss and a low-salt diet are recommended. Bariatric surgery has been shown to result in sustained reduction of ICP and weight loss ¹⁾. A 24% reduction in body weight is reported to lead to disease remission, but even a 5–15% weight loss is beneficial for resolution of papilledema ¹⁾.

Q Which is preferred: LP shunt or VP shunt?

Currently, many institutions prefer VP shunts. Compared to LP shunts, VP shunts have lower complication and revision rates, and tend to result in shorter hospital stays in the event of shunt failure.

6. Pathophysiology and Detailed Mechanism of Onset

Mechanism of Intracranial Pressure Elevation in IIH

The exact mechanism of ICP elevation in IIH is not fully understood. Dysregulation of CSF dynamics and involvement of metabolic and hormonal factors have been suggested²⁾.

The relationship between ICP and intracranial volume is shown by an S-shaped pressure-volume curve. For volume increases up to 30 cm³, compensatory mechanisms (such as displacement of intracranial venous blood) result in only minor ICP changes. Once compensatory mechanisms are exhausted, even a small volume increase can cause a steep rise in ICP²⁾.

Genetic and Environmental Factors

IIH is a multifactorial disease involving both genetic and environmental factors²⁾.

Genetic factors: Genome-wide association studies have identified candidate regions on chromosomes 5, 13, and 14. No Mendelian inheritance pattern has been established.
Environmental factors: Obesity and weight gain are the greatest risk factors. Obesity in women of reproductive age is particularly important.
Glia-neuro-vascular interface: Complex interactions among glial cells, neurons, and capillaries may contribute to increased ICP.
Intracranial venous hypertension: Venous sinus stenosis has been proposed as a primary factor in IIH.

Mechanisms of LP shunt failure

The causes of delayed LP shunt dysfunction are multifactorial.

Catheter obstruction: Narrowing of the lumen due to protein or debris in the CSF.
Catheter fracture or migration: Caused by long-term mechanical stress
Abdominal side issues: Omental wrapping of the catheter, adhesions, decreased peritoneal absorption capacity
Shunt dependency: Prolonged elevation of ICP increases the risk of optic atrophy

7. Latest Research and Future Perspectives (Investigational Reports)

Role of venous stent placement

Venous stent placement is attracting attention as a new treatment option for IIH.

In the UK, a randomized controlled trial (RCT) comparing venous stent placement with shunt surgery is ongoing¹⁾. Eligible patients are those with venous stenosis and proven pressure gradient who are intolerant or unresponsive to medical therapy. A drawback is the need for antiplatelet therapy for 6 months after surgery.

Research gaps and future directions

The following areas have been identified as priority research topics in IIH²⁾.

Elucidation of the etiology of IIH
Elucidation of the mechanism of headache onset
Exploration of new treatments
Examination of differences between acute and gradual vision loss
Development of visual function monitoring methods
Identification of disease biomarkers

Toshniwal et al. (2024) pointed out that existing drugs such as acetazolamide may show only limited efficacy in lowering ICP, and stated that the search for new drug targets is urgent ²⁾. Refinement of preclinical research is considered essential for understanding the pathophysiology of IIH and expanding treatment options.

8. References

Bonelli L, Menon V, Arnold AC, Mollan SP. Managing idiopathic intracranial hypertension in the eye clinic. Eye (Lond). 2024;38:2472-2481.
Toshniwal SS, Kinkar J, Chadha Y, et al. Navigating the Enigma: A Comprehensive Review of Idiopathic Intracranial Hypertension. Cureus. 2024;16(3):e56256. PMID:38623134. doi:10.7759/cureus.56256.
Lee R, Mortensen P, Raviskanthan S, Sadrameli S, Al-Zubidi N, Lee AG. Delayed Symptomatic Lumboperitoneal Shunt Malfunction 18 Years After Stability. J Neuroophthalmol. 2023;43(4):e169-e170. PMID: 35427286.

Related keywords